1. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV. Department of Health and Human Services. Available at
http://www.aidsinfo.nih.gov/ContentFiles/ AdultandAdolescentGL.pdf
. Accessed June 7, 2018
2. European AIDS Clinical Society. European guidelines for clinical management and treatment of HIV-1-infected adults in Europe, version 9.0. Available at
http://www.eacsociety.org/files/guidelines_9.0-english.pdf
. Accessed August 17, 2018.
3. de Boer MG, van der Berk GE, van Holten N, Oryszcyn JE, Dorama W, Moha DA, et al. Intolerance of dolutegravir-containing combination antiretroviral therapy regimens in real-life clinical practice. AIDS. 2016;30:2831–4.
4. Llibre JM, Esteve A, Miro JM, Mateo G, Curran A, Podzamczer D, Riera M. Discontinuation of DTG, EVG/c and RAL due to toxicity in a prospective cohort. In: Presented at 24rd annual conference on retroviruses and opportunistic infections (CROI); February 13–16 2017, Seattle, Washington, USA. Abstract P651.
5. Lee M, Eyer F, Felgenhauer N, Klinker H, Spinner C. Overdose of dolutegravir in combination with tenofovir disoproxil fumarate/emtricitabine in suicide attempt in a 21-year old patient. AIDS Res Ther. 2015;12:18.